Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis

This study has been completed.
Information provided by:
National Taiwan University Hospital Identifier:
First received: August 1, 2008
Last updated: August 5, 2008
Last verified: August 2008
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 1998
  Primary Completion Date: December 1998 (Final data collection date for primary outcome measure)